Drug Trial Radar · NCT02799069
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
571
Actual
Start
Apr 2008
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Biofrontera Bioscience GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Accovion GmbH
- First posted
- Jun 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.
Conditions
- Actinic Keratosis
Interventions
BF-200 ALADrug
topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
MAL CreamDrug
topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
VehicleDrug
topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITTTime frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment
- Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), PPTime frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment
- Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT) Illuminated With Narrow Spectrum Devices OnlyTime frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.